Abstract:Tumor development and metastasis are facilitated by the complex interactions between cancer cells and their microenvironment, which comprises stromal cells and extracellular matrix (ECM) components, among other factors. Stromal cells can adopt new phenotypes to promote tumor cell invasion. A deep understanding of the signaling pathways involved in cell-to-cell and cell-to-ECM interactions is needed to design effective intervention strategies that might interrupt these interactions. In this review, we describe the tumor microenvironment (TME) components and associated therapeutics. We discuss the clinical advances in the prevalent and newly discovered signaling pathways in the TME, the immune checkpoints and immunosuppressive chemokines, and currently used inhibitors targeting these pathways. These include both intrinsic and non-autonomous tumor cell signaling pathways in the TME: protein kinase C (PKC) signaling, Notch, and transforming growth factor (TGF-β) signaling, Endoplasmic Reticulum (ER) stress response, lactate signaling, Metabolic reprogramming, cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) and Siglec signaling pathways. We also discuss the recent advances in Programmed Cell Death Protein 1 (PD-1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4), T-cell immunoglobulin mucin-3 (TIM-3) and Lymphocyte Activating Gene 3 (LAG3) immune checkpoint inhibitors along with the C-C chemokine receptor 4 (CCR4)- C-C class chemokines 22 (CCL22)/ and 17 (CCL17), C-C chemokine receptor type 2 (CCR2)- chemokine (C-C motif) ligand 2 (CCL2), C-C chemokine receptor type 5 (CCR5)- chemokine (C-C motif) ligand 3 (CCL3) chemokine signaling axis in the TME. In addition, this review provides a holistic understanding of the TME as we discuss the three-dimensional and microfluidic models of the TME, which are believed to recapitulate the original characteristics of the patient tumor and hence may be used as a platform to study new mechanisms and screen for various anti-cancer therapies. We further discuss the systemic influences of gut microbiota in TME reprogramming and treatment response. Overall, this review provides a comprehensive analysis of the diverse and most critical signaling pathways in the TME, highlighting the associated newest and critical preclinical and clinical studies along with their underlying biology. We highlight the importance of the most recent technologies of microfluidics and lab-on-chip models for TME research and also present an overview of extrinsic factors, such as the inhabitant human microbiome, which have the potential to modulate TME biology and drug responses.

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

Modelling the tumor immune microenvironment for precision immunotherapy

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Biophysical and biochemical aspects of immune cell–tumor microenvironment interactions

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy

New horizons in tumor microenvironment biology: challenges and opportunities

The clinical role of the TME in solid cancer

Role of tumor microenvironment in cancer progression and therapeutic strategy

Tumor microenvironment signaling and therapeutics in cancer progression

Advances in targeting tumor microenvironment for immunotherapy

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

The breast cancer tumor microenvironment and precision medicine: immunogenicity and conditions favoring response to immunotherapy

Unraveling the Tumor Microenvironment: Insights into Cancer Metastasis and Therapeutic Strategies

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies

Breast cancer immune microenvironment: from pre-clinical models to clinical therapies

Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Modulation of T cell function and survival by the tumor microenvironment

Managing the TME to improve the efficacy of cancer therapy